Last reviewed · How we verify
Placebo (IP)
Placebo produces no pharmacological effect and serves as an inert control in clinical trials.
At a glance
| Generic name | Placebo (IP) |
|---|---|
| Also known as | irinotecan + cisplatin, Irrinotecan, Cisplatin |
| Sponsor | Centocor, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inactive substance used as a comparator in randomized controlled trials to assess the efficacy of an investigational drug by isolating the true pharmacological effect from placebo response and natural disease progression. It has no molecular target or mechanism of action.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis (PHASE2)
- A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures (PHASE2, PHASE3)
- Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk (PHASE3)
- Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis (PHASE4)
- Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (PHASE2, PHASE3)
- A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (PHASE2, PHASE3)
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus (PHASE3)
- CPL-01 in the Management of Postoperative Pain After Bunionectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (IP) CI brief — competitive landscape report
- Placebo (IP) updates RSS · CI watch RSS
- Centocor, Inc. portfolio CI